Table 1.

Clinical characteristics of Darier’s patients included in the cohort

ID	Age	Gender	Therapy at sampling	Age at onset	ODD score	DD score	Odour score	PGA
DD1	78	Female	Acitretin	19	27 ++	40	6oo	Moderate (3)
DD2	58	Female	None	14	37.5 +++	51.5	7ooo	Severe (4)
DD3	56	Female	LDN	15	50.5 +++	58.5	9ooo	Severe (4)
DD4	30	Female	LDN	19	16.5 +	31.5	1o	Mild (2)
DD5	55	Female	None	15	19 +	25	4oo	Mild (2)
DD6	45	Female	Laser	19	7 +	9	1o	Mild (2)
DD7	48	Female	None	25	29 ++	35	5oo	Moderate (3)
DD8	29	Male	Acitretin	13	59 +++	75	8ooo	Severe (4)
DD9	48	Male	Acitretin, ISTR	8	80 +++	96	10ooo	Severe (4)
DD10	58	Male	None	28	28 ++	33	3o	Moderate (3)
DD11	25	Male	Acitretin	19	23 ++	28	1o	Moderate (3)
DD12	52	Female	Acitretin	21	24 ++	30	1o	Moderate (2)
DD13	29	Male	Acitretin	14	24 ++	30	5oo	Moderate (3)
DD14	27	Male	None	15	20.5 +	25.5	2o	Mild (2)

ODD objective Darier’ disease score, DD Darier’ disease score, PGA physician global assessment, LDN low-dose naltrexone, ISTR isotretinoin, ODD score-based severity groups mild + , moderate ++ , severe +++ , Odour score-based groups: mild ^o, moderate ^oo and intense ^ooo; participant’s IDs were ordered according to the date of involvement in the study